03 September 2026
03 September 2026
The agreement includes option exercise fees, milestone payments, and royalties on net sales of products commercialised with ALT-B4 technology.
The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential.
HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue.
The agency’s latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.
Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.
The deal includes an upfront payment to Biocytogen, along with eligibility for milestone payments tied to specified objectives.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
